Strongbridge Biopharma Profile

USD 0.10  1.61%

Payment of 5652 shares by Cohen Fredric J of Strongbridge Biopharma subject to Rule 16b-3

Strongbridge Biopharma plc insider trading alert for payment of ordinary shares by Cohen Fredric J, Chief Medical Officer, on February 28, 2018. This event was filed by Strongbridge Biopharma Pl with SEC on 2018-02-28. Statement of changes in beneficial ownership - SEC Form 4 [view details]   

Strongbridge Biopharma Summary

Strongbridge Biopharma plc (SBBP) is traded on NASDAQ in USA. It is located in PENNSYLVANIA, U.S.A and employs 66 people. Strongbridge Biopharma is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 286.87 M. Strongbridge Biopharma plc conducts business under Healthcare sector and is part of Pharmaceutical Products industry. This company has 45.53 M outstanding shares of which 617.99 K shares are at this time shorted by private and institutional investors with about 1.85 trading days to cover. Strongbridge Biopharma plc currently holds about 92.41 M in cash with (54.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.03.
Check Strongbridge Biopharma Probability Of Bankruptcy

Ownership Allocation (%)

Target Price Odds Analysis

Odds Below 6.3HorizonTargetOdds Above 6.3
13.19%30 days 6.30 86.70%
Based on normal probability distribution, the odds of Strongbridge Biopharma to move above current price in 30 days from now is about 86.7% (This Strongbridge Biopharma plc probability density function shows the probability of Strongbridge Biopharma Stock to fall within a particular range of prices over 30 days) .

Top Holders

Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Caxton CorpCommon Shares5.4 M47.3 M
Nea Management Company LlcCommon Shares4.1 M36.7 M
View Strongbridge Biopharma Diagnostics

Selected Strongbridge Biopharma plc Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

Key Fundamentals

Strongbridge Biopharma Against Markets

Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for Strongbridge Biopharma plc are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. Strongbridge Biopharma plc was founded in 1996 and is headquartered in Trevose, Pennsylvania. Strongbridge Biopharma operates under Biotechnology classification in USA and traded on NASDAQ. It employs 66 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
NameStrongbridge Biopharma plc
CEO and President and DirectorMatthew PaulsView All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
InstrumentUSA Stock View All
Business Address900 Northbrook Drive
IndustryPharmaceutical Products
Contact Number610 254 9200
CurrencyUSD - US Dollar


Strongbridge Biopharma Analyst Recommendations
Target PriceAdvice# of Analysts
17.33Strong Buy3Odds
Strongbridge Biopharma plc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Strongbridge Biopharma Analyst Advice  


Strongbridge Biopharma Earnings Estimates
EPSEstimate Date
Quarterly Estimate-0.32March 23, 2017
Strongbridge Biopharma plc normalized analysts earnings estimates for actual as well as projected forward EPS values taken as an average expert opinion over time
Earnings Estimate  


Strongbridge Biopharma Corporate Directors
Richard Kollender Director
Garheng Kong Director, MBA
Marten Steen Director, Ph.D
Also please take a look at World Market Map. Please also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.